Central nervous system toxicity of metallic nanoparticles

Feng, Xin; Chen, Aijie; Zhang, Yanli; Wang, Jianfeng; Shao, Longquan; Wei, Limin

doi:10.2147/ijn.s78308

Cited by 71 publications

(31 citation statements)

References 178 publications

(141 reference statements)

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…Although the preclinical results are very promising, majority of these probes are composed of heavy metals and clinical translation may be hindered by the perceived acute and chronic toxicity 36. Thus, in this study, we chose HA as the lymphatic mapping agent after labeling with the near-infrared dye Cy5.5 (excitation 675nm, emission 694 nm).…”

Section: Discussionmentioning

confidence: 99%

Mapping Sentinel Lymph Node Metastasis by Dual-probe Optical Imaging

Yang¹,

Wang²,

Zhang³

et al. 2017

Theranostics

View full text Add to dashboard Cite

Purpose: Sentinel lymph node biopsy (SLNB) has emerged as the preferred standard procedure in patients with breast cancer, melanoma and other types of cancer. Herein, we developed a method to intra-operatively map SLNs and differentiate tumor metastases within SLNs at the same time, with the aim to provide more accurate and real-time intraoperative guidance. Experimental Design: Hyaluronic acid (HA), a ligand of lymphatic vessel endothelial hyaluronan receptor (LYVE)-1, is employed as a SLN mapping agent after being conjugated with a near-infrared fluorophore (Cy5.5). Different sized HAs (5, 10 and 20K) were tested in normal mice and mice with localized inflammation to optimize LN retention time and signal to background ratio. Cetuximab, an antibody against epidermal growth factor receptor (EGFR), and trastuzumab, an antibody against human epidermal growth factor receptor 2 (HER2), were labeled with near-infrared fluorophore (IRDye800) for detecting metastatic tumors. LN metastasis model was developed by hock injection of firefly luciferase engineered human head neck squamous carcinoma cancer UM-SCC-22B cells or human ovarian cancer SKOV-3 cells. The metastases within LNs were confirmed by bioluminescence imaging (BLI). IRDye800-Antibodies were intravenously administered 24 h before local administration of Cy5.5-HA. Optical imaging was then performed to identify nodal metastases. Results: Binding of HA with LYVE-1 was confirmed by ELISA and fluorescence staining. HA with a size of 10K was chosen based on the favorable migration and retention profile. After sequential administration of IRDye800-antibodies intravenously and Cy5.5-HA locally to a mouse model with LN metastases and fluorescence optical imaging, partially metastasized LNs were successfully distinguished from un-metastasized LNs and fully tumor occupied LNs, based on the different signal patterns. Conclusions: Fluorophore conjugated HA is a potential lymphatic mapping agent for SLNB. Dual-tracer imaging with the combination of lymphatic mapping agents and tumor targeting agents can identify tumor metastases within SLNs, thus may provide accurate and real-time intra-operative guidance to spare the time spent waiting for a biopsy result.

show abstract

Section: Discussionmentioning

confidence: 99%

Mapping Sentinel Lymph Node Metastasis by Dual-probe Optical Imaging

Yang¹,

Wang²,

Zhang³

et al. 2017

Theranostics

View full text Add to dashboard Cite

show abstract

“…A few other polymeric NPs were documented to exhibit enhanced targeting and efficacy, but only with specific pH and temperature (Barua & Mitragotri, 2014 ). In another case, certain metallic nano-carriers were reported to facilitate Aβ fibrillation mediated AD progression and were also involved in bio-accumulation mediated neurotoxicity (Wu et al., 2008 ; Feng et al., 2015 ). These reports cumulatively suggest that several features are involved in the interplay of NPs in biological systems.…”

Section: Challenges and Future Perspectivesmentioning

confidence: 99%

Therapeutic strategies and nano-drug delivery applications in management of ageing Alzheimer’s disease

et al. 2018

View full text Add to dashboard Cite

In recent years, the incidental rate of neurodegenerative disorders has increased proportionately with the aging population. Alzheimer’s disease (AD) is one of the most commonly reported neurodegenerative disorders, and it is estimated to increase by roughly 30% among the aged population. In spite of screening numerous drug candidates against various molecular targets of AD, only a few candidates – such as acetylcholinesterase inhibitors are currently utilized as an effective clinical therapy. However, targeted drug delivery of these drugs to the central nervous system (CNS) exhibits several limitations including meager solubility, low bioavailability, and reduced efficiency due to the impediments of the blood-brain barrier (BBB). Current advances in nanotechnology present opportunities to overcome such limitations in delivering active drug candidates. Nanodrug delivery systems are promising in targeting several therapeutic moieties by easing the penetration of drug molecules across the CNS and improving their bioavailability. Recently, a wide range of nano-carriers, such as polymers, emulsions, lipo-carriers, solid lipid carriers, carbon nanotubes, metal based carriers etc., have been adapted to develop successful therapeutics with sustained release and improved efficacy. Here, we discuss few recently updated nano-drug delivery applications that have been adapted in the field of AD therapeutics, and future prospects on potential molecular targets for nano-drug delivery systems.

show abstract

“…Toxicities associated with NPs in infectious agents are usually related to their causing damage such as generating ROS and oxidative DNA damage (Niazi and Gu, 2009). Additionally, NPs can be potentially dangerous to the central nervous system in some properties, such as lysosome dysfunction, autophagy, oxidative stress, and the activation of certain signaling pathways (Wei et al, 2015).…”

Section: The Role Of Metallic and Metal Oxide Nanoparticlementioning

confidence: 99%

Promising nanotherapy in treating leishmaniasis

Souza

Marins

Mathias

et al. 2018

International Journal of Pharmaceutics

View full text Add to dashboard Cite

Leishmaniases are infectious diseases caused by an intracellular protozoan in humans by 20 different species of Leishmania among more than 53 species. There are at least twelve million cases of infections worldwide and three hundred and fifty million people are at risk in at least 98 developing countries in Africa, South-East Asia, and the Americas. Only Brazil presented high burden for both visceral leishmaniasis (VL) and cutaneous (CL). Chemotherapy is the main means of dealing with this infection. Nevertheless, only a few effective drugs are available, and each has a particular disadvantage; toxicity and long-term regimens compromise most chemotherapeutic options, which decreases patient compliance and adherence to the treatment and consequently the emergence of drug-resistant strains. Nano drug delivery systems (NanoDDS) can direct antileishmanial drug substances for intracellular localization in macrophage-rich organs such as bone marrow, liver, and spleen. This strategy can improve the therapeutic efficacy and reduce the toxic effects of several antileishmanial drug substances. This review is an effort to comprehensively compile recent findings, with the aim of advancing understanding of the importance of nanotechnology for treating leishmaniases.

show abstract

Central nervous system toxicity of metallic nanoparticles

Cited by 71 publications

References 178 publications

Mapping Sentinel Lymph Node Metastasis by Dual-probe Optical Imaging

Mapping Sentinel Lymph Node Metastasis by Dual-probe Optical Imaging

Therapeutic strategies and nano-drug delivery applications in management of ageing Alzheimer’s disease

Promising nanotherapy in treating leishmaniasis

Contact Info

Product

Resources

About